Jennifer J. Gile

Nov 12, 2023 | nature.com | Jennifer J. Gile |Matthew J. Maurer |Jonas Paludo |Stephen Ansell |Thomas M Habermann |Thomas E Witzig | +4 more

AbstractOver the last two decades, the frontline therapy for mantle cell lymphoma (MCL) has evolved. However, the impact of subsequent lines of therapy on survival outcomes has not been well characterized. In this study, we investigated the treatment patterns and survival outcomes in patients with relapsed/refractory (R/R) MCL treated with second-line (2 L) therapy. Adult patients with newly diagnosed MCL from 2002 to 2015 were enrolled in a prospective cohort study.